SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma
Hodgkin lymphoma (HL) is an uncommon B cell lymphoid malignancy representing approximately 10–15 % of all lymphomas. HL is composed of two dis tinct disease entities; the more commonly diagnosed clas sical HL and the rare nodular lymphocyte-predominant HL. An accurate assessment of the stage of dise...
| Autores: | , , , , , , , , , |
|---|---|
| Tipo de documento: | artigo |
| Estado: | Versão publicada |
| Data de publicação: | 2015 |
| País: | España |
| Recursos: | Universidad de Sevilla (US) |
| Repositório: | idUS. Depósito de Investigación de la Universidad de Sevilla |
| OAI Identifier: | oai:idus.us.es:11441/156647 |
| Acesso em linha: | https://hdl.handle.net/11441/156647 https://doi.org/10.1007/s12094-015-1429-1 |
| Access Level: | Acceso aberto |
| Palavra-chave: | Oncohematology malignancies Hodgkin lymphoma Hodgkin lymphoma therapy |
| id |
ES_ed968a7ca2934b16f52f4ba0a02e23aa |
|---|---|
| oai_identifier_str |
oai:idus.us.es:11441/156647 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
SEOM clinical guidelines for the treatment of Hodgkin’s lymphomaRueda Domínguez, A.Alfaro Lizaso, J.Cruz Merino, Luis de laGumá i Padró, J.Quero Blanco, C.Gómez Codina, J.Llanos Muñoz, M.Martínez Banaclocha, N.Rodriguez Abreu, D.Provencio Pulla, M.Oncohematology malignanciesHodgkin lymphomaHodgkin lymphoma therapyHodgkin lymphoma (HL) is an uncommon B cell lymphoid malignancy representing approximately 10–15 % of all lymphomas. HL is composed of two dis tinct disease entities; the more commonly diagnosed clas sical HL and the rare nodular lymphocyte-predominant HL. An accurate assessment of the stage of disease and prog nostic factors that identify patients at low or high risk for recurrence are used to optimize therapy. Patients with early stage disease are treated with combined modality strategies using abbreviated courses of combination chemotherapy followed by involved-field radiation therapy, while those with advanced stage disease receive a longer course of chemotherapy often without radiation therapy. High-dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. Brentuximab vedotin should be considered for patients who fail HDCT with ASCT.SpringerMedicinaCTS151: Bioquímica médica2015info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttps://hdl.handle.net/11441/156647https://doi.org/10.1007/s12094-015-1429-1reponame:idUS. Depósito de Investigación de la Universidad de Sevillainstname:Universidad de Sevilla (US)InglésClinical and Translational Oncology, 17 (12), 100507-1013.https://link.springer.com/article/10.1007/s12094-015-1429-1info:eu-repo/semantics/openAccessoai:idus.us.es:11441/1566472026-06-17T12:51:07Z |
| dc.title.none.fl_str_mv |
SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma |
| title |
SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma |
| spellingShingle |
SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma Rueda Domínguez, A. Oncohematology malignancies Hodgkin lymphoma Hodgkin lymphoma therapy |
| title_short |
SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma |
| title_full |
SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma |
| title_fullStr |
SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma |
| title_full_unstemmed |
SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma |
| title_sort |
SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma |
| dc.creator.none.fl_str_mv |
Rueda Domínguez, A. Alfaro Lizaso, J. Cruz Merino, Luis de la Gumá i Padró, J. Quero Blanco, C. Gómez Codina, J. Llanos Muñoz, M. Martínez Banaclocha, N. Rodriguez Abreu, D. Provencio Pulla, M. |
| author |
Rueda Domínguez, A. |
| author_facet |
Rueda Domínguez, A. Alfaro Lizaso, J. Cruz Merino, Luis de la Gumá i Padró, J. Quero Blanco, C. Gómez Codina, J. Llanos Muñoz, M. Martínez Banaclocha, N. Rodriguez Abreu, D. Provencio Pulla, M. |
| author_role |
author |
| author2 |
Alfaro Lizaso, J. Cruz Merino, Luis de la Gumá i Padró, J. Quero Blanco, C. Gómez Codina, J. Llanos Muñoz, M. Martínez Banaclocha, N. Rodriguez Abreu, D. Provencio Pulla, M. |
| author2_role |
author author author author author author author author author |
| dc.contributor.none.fl_str_mv |
Medicina CTS151: Bioquímica médica |
| dc.subject.none.fl_str_mv |
Oncohematology malignancies Hodgkin lymphoma Hodgkin lymphoma therapy |
| topic |
Oncohematology malignancies Hodgkin lymphoma Hodgkin lymphoma therapy |
| description |
Hodgkin lymphoma (HL) is an uncommon B cell lymphoid malignancy representing approximately 10–15 % of all lymphomas. HL is composed of two dis tinct disease entities; the more commonly diagnosed clas sical HL and the rare nodular lymphocyte-predominant HL. An accurate assessment of the stage of disease and prog nostic factors that identify patients at low or high risk for recurrence are used to optimize therapy. Patients with early stage disease are treated with combined modality strategies using abbreviated courses of combination chemotherapy followed by involved-field radiation therapy, while those with advanced stage disease receive a longer course of chemotherapy often without radiation therapy. High-dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. Brentuximab vedotin should be considered for patients who fail HDCT with ASCT. |
| publishDate |
2015 |
| dc.date.none.fl_str_mv |
2015 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
https://hdl.handle.net/11441/156647 https://doi.org/10.1007/s12094-015-1429-1 |
| url |
https://hdl.handle.net/11441/156647 https://doi.org/10.1007/s12094-015-1429-1 |
| dc.language.none.fl_str_mv |
Inglés |
| language_invalid_str_mv |
Inglés |
| dc.relation.none.fl_str_mv |
Clinical and Translational Oncology, 17 (12), 100507-1013. https://link.springer.com/article/10.1007/s12094-015-1429-1 |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf application/pdf |
| dc.publisher.none.fl_str_mv |
Springer |
| publisher.none.fl_str_mv |
Springer |
| dc.source.none.fl_str_mv |
reponame:idUS. Depósito de Investigación de la Universidad de Sevilla instname:Universidad de Sevilla (US) |
| instname_str |
Universidad de Sevilla (US) |
| reponame_str |
idUS. Depósito de Investigación de la Universidad de Sevilla |
| collection |
idUS. Depósito de Investigación de la Universidad de Sevilla |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869423517389291520 |
| score |
15.812429 |